SciTech Development LLC to Present at 2018 NYC Oncology Investor Conference
Mr. Holsapple is scheduled to present on Wednesday, October 31st at 10:25 am EST. Accredited investors are also invited to request a one-on-one meeting with SciTech Development's management during the conference through the One-on-One Meeting Space.
SciTech is seeking funding to bring its lead product ST-001 to market for the treatment of T-cell non-Hodgkin's lymphoma (NHL) and small cell lung cancer (SCLC). ST-001 may be used as a standalone drug or as an ancillary treatment with immunotherapy. SciTech's product pipeline also includes treatment for several other cancer indications.
The company has submitted an Investigational New Drug (IND) Application for ST-001 in the treatment of NHL. The FDA has already granted Orphan Drug Status for ST-001 in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
Information regarding SciTech's nano formulation technology and oncology drug product ST-001 is available from SciTech Development, LLC by calling (313) 938-5517 or online at https://www.scitechdevelopment.com/
About SciTech Development
SciTech Development, LLC is a clinical stage oncology drug company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland.
Selected Product Pipeline
ST-001 – Intravenous fenretinide formulation for the treatment of NHL.
ST-002 – Topical formulation for the treatment of various skin cancers and bed sores.
ST-003 – Intravenous formulation for the treatment of small cell lung cancer (SCLC).
ST-004 – Intravenous formulation for the treatment of metastatic breast cancer (MBC).
ST-005 – Intravenous formulation for the treatment of neuroblastoma (pediatric cancer).
ST-006 – Intravenous formulation for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).
About The NYC Oncology Investor Conference
The NYC Oncology Investor Conference 2018 hosted by OneMed Forum, and sponsored by the National Foundation for Cancer Research, the International Cancer Impact Fund, Klosters Innovation Partners, Venable Law Firm, Torreya Partners, and Marcum is the leading conference for early-stage private and public cancer investing. More information is available from the conference website (https://www.nyconcologyconference.com/)
This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. In particular, the words "believes," "expects," "intends," "plans," "anticipates,"
For More Information:
SciTech Development, LLC
SciTech Development, LLC